Ahmad Tarhini, MD
Hematology & Oncology · Pittsburgh, PANPI 1811934755
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $153,987 of the $216,423 with a category attached, or 71.2%. 17 manufacturers reported payments, led by Merck at 31.5% of the total. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $1534.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$68K
- Regeneron$32K
- E.r. Squibb & Sons, L.L.C.$31K
- Partner Therapeutics, Inc.$18K
- F. Hoffmann-la Roche AG$16K
- Novartis$15K
- plus $35K from 11 others
Across 692 payments — averaging $10,473 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.4M
- Regeneron$1.4M
- Pfizer$691K
- Genentech, Inc.$569K
- Novartis$443K
- E.r. Squibb & Sons, L.L.C.$430K
- plus $1.3M from 11 others
What the payments were for
- Consulting fees$153,98771%
- Speaking & faculty fees$19,8629%
- Travel & lodging$39,96518%
- Food & beverage$2,5351%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 55 | $68,196 |
| Regeneron | 17 | $32,406 |
| E.r. Squibb & Sons, L.L.C. | 25 | $31,048 |
| Partner Therapeutics, Inc. | 5 | $18,302 |
| F. Hoffmann-la Roche AG | 4 | $16,073 |
| Novartis | 13 | $15,332 |
| Sanofi | 3 | $12,777 |
| Eisai Inc. | 3 | $5,000 |
| Genentech USA, Inc. | 3 | $4,505 |
| Regeneron Healthcare Solutions, Inc. | 1 | $3,275 |
| AstraZeneca | 1 | $2,740 |
| Array Biopharma Inc | 5 | $2,538 |
| Clinigen, Inc. | 2 | $2,245 |
| Bayer | 1 | $1,000 |
| Modernatx, Inc. | 1 | $650 |
| Genentech, Inc. | 1 | $191 |
| Sun Pharmaceutical Industries Inc. | 1 | $146 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$216,423 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 13 | $119 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Pittsburgh
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Alexander BarsoukPittsburgh$674K
- Hashem YounesPittsburgh$435K
- Taofeek OwonikokoPittsburgh$346K
- Jason LukePittsburgh$300K
- Diwakar DavarPittsburgh$104K
- Jing Zhou HouPittsburgh$78K
- Vikram GorantlaPittsburgh$62K
- Stanley MarksPittsburgh$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.